COMMUNIQUÉS West-GlobeNewswire

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
14/05/2026
Data spans seven presentations across both solid tumors and hematologic malignancies , providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus capivasertib [...]
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
14/05/2026
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Pure Harvest Corporate Group (OTC: PHCG), Operating as Mixie Technologies, Announces HoloTwin Launch of AI-Powered HT Scan
14/05/2026
CES 2026 award winner combines an iOS device, AI guidance, and intelligent modules trained on real-time IoT data to deliver enterprise-grade 3D twins through an accelerated digital twin capture workflow DENVER, May 14, [...]
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
14/05/2026
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post- [...]
Kyverna Therapeutics to Present at Upcoming Investor Conferences
14/05/2026
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases [...]
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC [...]
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
14/05/2026
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA [...]
Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026
14/05/2026
PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced [...]
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built [...]
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
14/05/2026
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a best-in- [...]
FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
14/05/2026
Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U. [...]
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
14/05/2026
GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase Company [...]
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
14/05/2026
Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across [...]
CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale’s Biotech Spinouts
14/05/2026
New Haven-based biotech venture creation platform focused on launching early-stage therapeutics companies from breakthrough Yale University research NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- CapeHaven , LLC, a [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
14/05/2026
~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE [...]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
14/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
14/05/2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) ( [...]
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
14/05/2026
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas [...]

Pages